// App-Quantinova.ai

275 : Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials

Researchers

Presenter

  • Maya Buch

Principal Investigators

  • Gerd Burmester

  • Xavier Mariette

  • Christina Charles-Schoeman

  • Vijay Rajendran

  • Pieter-Jan Stiers

  • Agustin Cerani

  • Paul Van Hoek

  • Katrien Van Beneden

  • Yoshiya Tanaka

  • Hendrik Schulze-Koops

  • Rene Westhovens

  • Ennio Giulio Favalli

Medical Centers

  • University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

  • Charite-University Medicine Berlin, Berlin, Germany

  • Paris-Saclay University, Rueil Malmaison, Ile-de-France, France

  • Division of Hematoogy/Oncology, University of California, Los Angeles, Santa Monica, CA

  • Galapagos NV, Gent, Belgium

  • Galapagos, Mechelen, Belgium

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Ludwig Maximilians University Munich, Munich, Germany

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy

Locations

  • United Kingdom

  • Germany

  • France

  • United States

  • Belgium

  • Japan

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Angiology

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

  • Blood/haematological Diseases

Disease

  • Peripheral artery disease

  • Venous thrombosis

  • Dyslipidemia

  • Hypertension

  • Skin carcinoma

  • Diabetes

  • Solid malignancies

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02092467

  • NCT01668641

  • NCT01894516

  • NCT02889796

  • NCT02873936

  • NCT02886728

  • NCT02065700

  • NCT03025308

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved